Pfizer Inc. acquires Metsera, Inc., beating Novo Nordisk, for up to $86.25/share. Click for my analysis of the deal and what ...

The announcement of the deal signaled an end to the bidding war for Metsera between Pfizer and Novo Nordisk, the Danish maker ...

Pfizer (PFE) wins Metsera (MTSR) buyout after a heated bidding war with Novo Nordisk (NVO), securing a $10B deal for the ...

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE, “Pfizer”) will present data across its infectious disease portfolio at the upcoming IDWeek 2025 congress, held in Atlanta from October 19-22, 2025.

Pfizer Inc. (NYSE: PFE, “Pfizer”) will present data across its infectious disease portfolio at the upcoming IDWeek 2025 congress, held in Atlanta from October 19-22, 2025. Data in 46 abstracts from ...

Jeanine Skowronski is an editor, writer, and journalist with more than 15 years of experience in personal finance and business, including roles at Bankrate, CreditCards.com, and Policygenius. Her work ...

This is read by an automated voice. Please report any issues or inconsistencies here. President Trump’s deal with Pfizer on drug prices won’t do much for American patients, but it’s great for Pfizer.

Health-care companies fell, giving back some recent gains related to a compromise between the U.S. and one major drug maker. Shares of Pfizer, which has agreed to sell Americans pharmaceuticals at a ...

A recently announced initiative between Pfizer and the Trump administration to lower U.S. drug prices will likely have minimal effects at the pharmacy counter, The New York Times reported Oct. 1. On ...

Health-care companies ticked down, paring recent gains as anxiety about the outlook for tariffs and regulation lingered. Pfizer's deal supporting the TrumpRx direct-to-consumer pharmaceutical website ...

President Trump said he expects to reach pricing deals with more drug companies following the Pfizer announcement. Photo: Win McNamee/Getty Images This is an online version of the Markets A.M.

Listen to more stories on the Noa app. Sign up for Trump’s Return, a newsletter featuring coverage of the second Trump presidency. Donald Trump, always one to tout his knack for dealmaking, declared ...